Investor Overview

Oncolytics Biotech, Inc.

Oncolytics is focused on obtaining regulatory approval for pelareorep for metastatic breast cancer and pancreatic cancer, indications with continued and considerable unmet needs. Based on very compelling data, Oncolytics believes that advancing pelareorep through late-stage clinical testing, submission and registration in these indications present the highest chance of success with the greatest commercial opportunity.

Investor Relations Contact

Jon Patton
Director of Investor Relations & Communication

Email Alerts Sign-Up